NASDAQ: CLSD - Clearside Biomedical, Inc.

Yield per half year: -22.76%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Clearside Biomedical, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc.

more details
has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2016-06-02
ISIN US1850631045
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://clearsidebio.com
Цена ао 1.69
Change price per day: +2.15% (0.93)
Change price per week: +8.91% (0.8723)
Change price per month: -11.21% (1.07)
Change price per 3 month: -18.1% (1.16)
Change price per half year: -22.76% (1.23)
Change price per year: -18.8% (1.17)
Change price per 3 year: -67.24% (2.9)
Change price per 5 year: -24.6% (1.26)
Change price per 10 year: 0% (0.95)
Change price per year to date: -9.52% (1.05)
All parameters

Underestimation

Title Value Grade
P/S 7.81 1
P/BV -4.04 0
P/E 0 0
EV/EBITDA -3.16 0
Total: 3.75

Efficiency

Title Value Grade
ROA, % -95.49 0
ROE, % 204.15 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -1.74 10
Total: 7.6

Growth impulse

Title Value Grade
Yield Revenue, % 273.91 10
Yield Ebitda, % -23.9 0
Yield EPS, % -34.35 0
Total: 2.2
More

Institutions Volume Share, %
Vanguard Group Inc 2176316 2.91
Carmignac Gestion 2132744 2.85
Blackrock Inc. 759743 1.02
Geode Capital Management, LLC 490690 0.66
Renaissance Technologies, LLC 384689 0.51
State Street Corporation 193363 0.26
Bridgeway Capital Management, Inc. 175600 0.24
First Manhattan Company 175000 0.23
Johnson & Johnson 169629 0.23
Morgan Stanley 144434 0.19

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.02367 17.09 1.54048



Head Job title Payment Year of birth
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. President, CEO & Director 836.15k 1952 (73 years)
Mr. Charles A. Deignan Chief Financial Officer 568.68k 1964 (61 year)
Ms. Jenny R. Kobin Head of Investor Relations N/A 1967 (58 years)
Mr. Rick McElheny Senior Vice President of Corporate Development & Alliance Management N/A
Mr. Rafael V. Andino Senior Vice President of Engineering & Manufacturing N/A 1965 (60 years)
Ms. Susan L. Coultas Ph.D. Chief Clinical Officer N/A
Mr. Leslie B. Zacks Secretary N/A 1969 (56 years)
Dr. Ngai Hang Chong FRCOphth, FRCS, M.B.A., M.D. Chief Medical Officer

Address: United States, Alpharetta. GA, 900 North Point Parkway - open in Google maps, open in Yandex maps
Website: https://clearsidebio.com